Updated Jul 16, 2026
Fuhrman Alan has filed 1 SEC Form 4 filing across 1 company in the last 90 days — buying. Lifetime open-market purchases: $152K.
Alan Fuhrman is a corporate executive known for his roles as Director and Chief Financial Officer at Tyra Biosciences, Inc. and SpringWorks Therapeutics, Inc. He has been involved in the biotechnology sector, focusing on financial management and strategic oversight.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-07 | TYRA | Tyra Biosciences, Inc. | A — Grant or award | 20.0K | $0.00 | |
| 2026-03-17 | TYRA | Tyra Biosciences, Inc. | A — Grant or award | 1.4K | $9.13 | $13K |
| 2025-09-15 | TYRA | Tyra Biosciences, Inc. | A — Grant or award | 701 | $9.13 | $6K |
| 2025-07-01 | SWTX | SpringWorks Therapeutics, Inc. | D — Derivative transaction | 24.7K | — | |
| 2025-05-14 | SWTX | SpringWorks Therapeutics, Inc. | A — Grant or award | 10.1K | $0.00 | |
| 2024-11-01 | TYRA | Tyra Biosciences, Inc. | P — Open-market purchase | 9.5K | $16.00 | $152K |
Alan Fuhrman is a corporate executive known for his roles as Director and Chief Financial Officer at Tyra Biosciences, Inc. and SpringWorks Therapeutics, Inc. He has been involved in the biotechnology sector, focusing on financial management and strategic oversight.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 1 open-market purchases ($152K) and 0 open-market sales () across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Fuhrman Alan profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.